Somatostatin receptor-1 induces cell cycle arrest and inhibits tumor growth in pancreatic cancer

Cancer Science

Volumn 99, Issue 11, 2008, Pages 2218-2223

  Li, Min ^a   Wang, Xiaochi ^b   Li, Wei ^c   Li, Fei ^a   Yang, Hui ^a   Wang, Hao ^a   Brunicardi, F Charles ^a   Chen, Changyi ^a   Yao, Qizhi ^a   Fisher, William E ^a  

^a MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c SHANDONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; SOMATOSTATIN RECEPTOR 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GENE THERAPY; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION; GENE FUNCTION; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; MITOSIS INHIBITION; MOUSE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; TUMOR VOLUME;

ANIMALS; CELL CYCLE; CELL LINE, TUMOR; DOWN-REGULATION; HUMANS; MALE; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; PANCREATIC NEOPLASMS; RECEPTORS, SOMATOSTATIN; RNA, MESSENGER; TRANSFECTION; TRANSPLANTATION, HETEROLOGOUS;

EID: 55449137351     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2008.00940.x     Document Type: Article

References (41)

1. Li D, Xie K, Wolff R, Abbruzzese JL. Pancreatic cancer. Lancet 2004; 363: 1049-57.
2. Warshaw AL, Fernandez-del Castillo C. Pancreatic carcinoma. N Engl J Med 1992; 326: 455-65.
3. Fisher WE, Berger DH. Angiogenesis and antiangiogenic strategies in pancreatic cancer. Int J Gastrointest Cancer 2003; 33: 79-88.
4. Bousquet C, Puente E, Buscail L, Vaysse N, Susini C. Antiproliferative effect of somatostatin and analogs. Chemotherapy 2001; 47(Suppl 2): 30-9.
5. Hejna M, Schmidinger M, Raderer M. The clinical role of somatostatin analogues as antineoplastic agents: Much ado about nothing? Ann Oncol 2002; 13: 653-68.
6. Hershberger RE, Newman BL, Florio T et al. The somatostatin receptors SSTR1 and SSTR2 are coupled to inhibition of adenylyl cyclase in Chinese hamster ovary cells via pertussis toxin-sensitive pathways. Endocrinology 1994; 134: 1277-85.
7. Zatelli MC, Piccin D, Tagliati F et al. Somatostatin receptor subtype 1 selective activation in human growth hormone (GH)- and prolactin (PRL)-secreting pituitary adenomas: Effects on cell viability, GH, and PRL secretion. J Clin Endocrinol Metab 2003; 88: 2797-802.
8. Kikutsuji T, Harada M, Tashiro S et al. Expression of somatostatin receptor subtypes and growth inhibition in human exocrine pancreatic cancers. J Hepatobiliary Pancreat Surg 2000; 7: 496-503.
9. Guillermet J, Saint-Laurent N, Rochaix P et al. Somatostatin receptor subtype 2 sensitizes human pancreatic cancer cells to death ligand-induced apoptosis. Proc Natl Acad Sci USA 2003; 100: 155-60.
10. Rochaix P, Delesque N, Esteve JP et al. Gene therapy for pancreatic carcinoma: Local and distant antitumor effects after somatostatin receptor sst2 gene transfer. Hum Gene Ther 1999; 10: 995-1008.
11. Celinski SA, Fisher WE, Amaya F et al. Somatostatin receptor gene transfer inhibits established pancreatic cancer xenografts. J Surg Res 2003; 115: 41-7.
12. Li M, Zhang R, Li F et al. Transfection of SSTR-1 and SSTR-2 inhibits Panc-1 cell proliferation and renders Panc-1 cells responsive to somatostatin analogue. J Am Coll Surg 2005; 201: 571-8.
13. Klijn JG, Hoff AM, Planting AS et al. Treatment of patients with metastatic pancreatic and gastrointestinal tumours with the somatostatin analogue Sandostatin: A phase II study including endocrine effects. Br J Cancer 1990; 62: 627-30.
14. Canobbio L, Boccardo F, Cannata D, Gallotti P, Epis R. Treatment of advanced pancreatic carcinoma with the somatostatin analogue BIM 23014. Preliminary results of a pilot study. Cancer 1992; 69: 648-50.
15. Huguier M, Samama G, Testart J et al. Treatment of adenocarcinoma of the pancreas with somatostatin and gonadoliberin (luteinizing hormone-releasing hormone). The French Associations for Surgical Research. Am J Surg 1992; 164: 348-53.
16. Raderer M, Hamilton G, Kurtaran A et al. Treatment of advanced pancreatic cancer with the long-acting somatostatin analogue lanreotide: in vitro and in vivo results. Br J Cancer 1999; 79: 535-7.
17. Li M, Yang H, Chai H et al. Pancreatic carcinoma cells express neuropilins and vascular endothelial growth factor, but not vascular endothelial growth factor receptors. Cancer 2004; 101: 2341-50.
18. Li M, Zhai Q, Bharadwaj U et al. Cyclophilin A is overexpressed in human pancreatic cancer cells and stimulates cell proliferation through CD147. Cancer 2006; 106: 2284-94.
19. Li M, Li W, Kim HJ, Yao Q, Chen C, Fisher WE. Characterization of somatostatin receptor expression in human pancreatic cancer using real-time RT-PCR. J Surg Res 2004; 119: 130-7.
20. Li M, Zhang Y, Liu Z et al. Aberrant expression of zinc transporter ZIP4 (SLC39A4) significantly contributes to human pancreatic cancer pathogenesis and progression. Proc Natl Acad Sci USA 2007; 104: 18.636-41.
21. Li M, Bharadwaj U, Zhang R et al. Mesothelin is a malignant factor and therapeutic vaccine target for pancreatic cancer. Mol Cancer Ther 2008; 7: 286-96.
22. Fisher WE, Wu Y, Amaya F, Berger DH. Somatostatin receptor subtype 2 gene therapy inhibits pancreatic cancer in vitro. J Surg Res 2002; 105: 58-64.
23. Lahlou H, Saint-Laurent N, Esteve JP et al. sst2 Somatostatin receptor inhibits cell proliferation through Ras-, Rap1-, and B-Raf-dependent ERK2 activation. J Biol Chem 2003; 278: 39.356-71.
24. Longnecker DS, Shinozuka H, Dekker A. Focal acinar cell dysplasia in human pancreas. Cancer 1980; 45: 534-40.
25. Pour PM, Schmied B. The link between exocrine pancreatic cancer and the endocrine pancreas. Int J Pancreatol 1999; 25: 77-87.
26. Pour PM, Pandey KK, Batra SK. What is the origin of pancreatic adenocarcinoma? Mol Cancer 2003; 2: 13.
27. Nehete PN, Lewis DE, Tang DN, Pollack MS, Sastry KJ. Presence of HLA-C-restricted cytotoxic T-lymphocyte responses in long-term nonprogressors infected with human immunodeficiency virus. Viral Immunol 1998; 11: 119-29.
28. Reubi JC, Kappeler A, Waser B, Schonbrunn A, Laissue J. Immunohistochemical localization of somatostatin receptor sst2A in human pancreatic islets. J Clin Endocrinol Metab 1998; 83: 3746-9.
29. Kumar U, Sasi R, Suresh S et al. Subtype-selective expression of the five somatostatin receptors (hSSTR1-5) in human pancreatic islet cells: a quantitative double-label immunohistochemical analysis. Diabetes 1999; 48: 77-85.
30. Tang C, Biemond I, Appel MJ, Visser CJ, Woutersen RA, Lamers CB. Expression of receptors for gut peptides in pancreata of BOP-treated and control hamsters. Carcinogenesis 1996; 17: 2171-5.
31. Caldas C, Hahn SA, da Costa LT et al. Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat Genet 1994; 8: 27-32.
32. Goggins M, Kern SE, Offerhaus JA, Hruban RH. Progress in cancer genetics: Lessons from pancreatic cancer. Ann Oncol 1999; 10(Suppl 4): 4-8.
33. Kar R, Sen S, Singh A et al. Role of apoptotic regulators in human epithelial ovarian cancer. Cancer Biol Ther 2007; 6.
34. Lopez F, Ferjoux G, Cordelier P et al. Neuronal nitric oxide synthase: A substrate for SHP-1 involved in sst2 somatostatin receptor growth inhibitory signaling. Faseb J 2001; 15: 2300-2.
35. Lopez F, Esteve JP, Buscail L et al. The tyrosine phosphatase SHP-1 associates with the sst2 somatostatin receptor and is an essential component of sst2-mediated inhibitory growth signaling. J Biol Chem 1997; 272: 24.448-54.
36. Bousquet C, Delesque N, Lopez F et al. sst2 somatostatin receptor mediates negative regulation of insulin receptor signaling through the tyrosine phosphatase SHP-1. J Biol Chem 1998; 273: 7099-106.
37. Ferjoux G, Lopez F, Esteve JP et al. Critical role of Src and SHP-2 in sst2 somatostatin receptor-mediated activation of SHP-1 and inhibition of cell proliferation. Mol Biol Cell 2003; 14: 3911-28.
38. Florio T, Yao H, Carey KD, Dillon TJ, Stork PJ. Somatostatin activation of mitogen-activated protein kinase via somatostatin receptor 1 (SSTR1). Mol Endocrinol 1999; 13: 24-37.
39. Florio T, Thellung S, Arena S et al. Somatostatin receptor 1 (SSTR1)-mediated inhibition of cell proliferation correlates with the activation of the MAP kinase cascade: Role of the phosphotyrosine phosphatase SHP-2. J Physiol Paris 2000; 94: 239-50.
40. Patel GP, Ma S, Bag J. The autoregulatory translational control element of poly(A)-binding protein mRNA forms a heteromeric ribonucleoprotein complex. Nucleic Acids Res 2005; 33: 7074-89.
41. Benali N, Cordelier P, Calise D et al. Inhibition of growth and metastatic progression of pancreatic carcinoma in hamster after somatostatin receptor subtype 2 (sst2) gene expression and administration of cytotoxic somatostatin analog AN-238. Proc Natl Acad Sci USA 2000; 97: 9180-5.